Clinical Trial Update: Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas [Phase 1]

View source ↗

Summary

Itacitinib was studied in a Phase 1 trial for patients with refractory metastatic/advanced sarcomas, but the study status is TERMINATED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chondrosarcoma
• Leiomyosarcoma
• Myxoid Liposarcoma
• Round Cell Liposarcoma
• Soft Tissue Sarcoma
• Synovial Sarcoma
• Undifferentiated Pleomorphic Sarcoma

Drugs mentioned

• Itacitinib (itacitinib)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma | Phase 1 | Status: TERMINATED